A 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. Pelitinib irreversibly binds covalently to epidermal growth factor receptors (EGFR) ErbB-1, -2 and -4, thereby inhibiting receptor phosphorylation and signal transduction and resulting in apoptosis and suppression of proliferation in tumor cells that overexpress these receptors. or A substance being studied in the treatment of some types of cancer. It blocks the action of certain proteins that are part of the epidermal growth factor receptor (EGFR) family of proteins. These proteins may be found in increased amounts on the surface of some types of cancer cells. Blocking the action of these proteins may stop cancer cells from growing and may kill cancer cells. Pelitinib is a type of EGFR inhibitor. Also called EKB-569.